|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400079383 |
|
最近更新日期: Date of Last Refreshed on: |
2024-01-02 10:48:06 |
|
注册时间: Date of Registration: |
2024-01-02 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
经皮穴位电刺激联合常规西药治疗慢性冠脉综合征的临床效应及氧化脂质组学研究 |
|
Public title: |
Clinical Effect and Oxylipidomics Study of Transcutaneous Electrical Acupoint Stimulation Combined with Conventional Western Medicine on Chronic Coronary Syndrome |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
经皮穴位电刺激足三里/内关治疗慢性冠脉综合征多中心随机对照试验 |
|
Scientific title: |
Transcutaneous Electrical Acupoint Stimulation of ST36/PC6 for the treatment of chronic coronary syndrome: a multicenter randomized controlled trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李梦琪 |
研究负责人: |
王洪峰 |
|
Applicant: |
Mengqi Li |
Study leader: |
Hongfeng Wang |
|
申请注册联系人电话: Applicant telephone: |
+86 178 4333 2070 |
研究负责人电话:
Study leader's |
+86 431 8671 4973 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
mengering123@163.com |
研究负责人电子邮件: Study leader's E-mail: |
mengering123@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
长春市南关区博硕路1035号 |
研究负责人通讯地址: |
长春市南关区博硕路1035号 |
|
Applicant address: |
1035 Boshuo Road, Nanguan District, Changchun City |
Study leader's address: |
1035 Boshuo Road, Nanguan District, Changchun City |
|
申请注册联系人邮政编码: Applicant postcode: |
130117 |
研究负责人邮政编码: Study leader's postcode: |
130117 |
|
申请人所在单位: |
长春中医药大学 |
||
|
Applicant's institution: |
Changchun University of Chinese Medicine |
||
|
研究负责人所在单位: |
长春中医药大学附属第三临床医院 |
||
|
Affiliation of the Leader: |
The Third Affiliated Hospital of Changchun University of Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
CZDSFYLL2023-021-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
长春中医药大学附属第三临床医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of the Third Affiliated Clinical Hospital of Changchun University of Traditional Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-05-29 00:00:00 | ||
|
伦理委员会联系人: |
张晓闻 |
||
|
Contact Name of the ethic committee: |
Xiaowen Zhang |
||
|
伦理委员会联系地址: |
长春市净月高新技术产业开发区净月大街1643号 |
||
|
Contact Address of the ethic committee: |
1643 Jingyue Street, Jingyue High tech Industrial Development Zone, Changchun City |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 431 8991 2033 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
长春中医药大学附属第三临床医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Third Affiliated Hospital of Changchun University of Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
长春市净月高新技术产业开发区净月大街1643号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
1643 Jingyue Street, Jingyue High tech Industrial Development Zone, Changchun City |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家重点研发计划 |
||||||||||||||||||||||
|
Source(s) of funding: |
National Key Research and Development Program of China |
||||||||||||||||||||||
|
研究疾病: |
慢性冠脉综合征 |
||||||||||||||||||||||
|
Target disease: |
Chronic Coronary Syndrome |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
IV期临床试验 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
系统阐述经皮穴位电刺激改善慢性冠脉综合征的临床效应及氧化脂质代谢机制 |
||||||||||||||||||||||
|
Objectives of Study: |
Systematically elucidate the clinical effects and the mechanism of oxidative lipid metabolism of transcutaneous electrical acupoint stimulation combined with conventional western medicine on chronic coronary syndrome. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)符合2019年ESC《慢性冠脉综合征的诊断与指南》诊断标准; (2)稳定型心绞痛; (3)心绞痛分级标准参照加拿大心血管学会心绞痛严重程度分级分为I、II、III级; (4)年龄30~80岁,男女不限; (5)心绞痛≥3个月,每周心绞痛发作次数≥2次; (6)签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Comply with the diagnostic criteria of the 2019 ESC "Diagnosis and Guidelines for Chronic Coronary Syndrome"; (2) Stable angina pectoris; (3) The classification criteria for angina pectoris are based on the severity classification of angina pectoris by the Canadian Cardiovascular Society, which is divided into levels I, II, and III; (4) Age range from 30 to 80 years old, regardless of gender; (5) Angina pectoris ≥ 3 months, with ≥ 2 episodes per week; (6) Sign an informed consent form. |
||||||||||||||||||||||
|
排除标准: |
(1)血压、血糖控制不良者; (2)重度心肺功能不全、严重心律失常、动脉重度狭窄、夹层等严重心血管疾病者; (3)伴有严重脑血管疾病、肝、肾或血液系统疾病或恶性肿瘤患者; (4)有出血倾向或过敏体质者; (5)装心脏起搏器患者; (6)孕期、哺乳期妇女,或近半年有生育要求者; (7)合并精神疾患或不愿合作者; (8)近3个月内参加过或正在参加其他临床试验者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Poor control of blood pressure and blood sugar; (2) Severe cardiovascular diseases such as severe cardiopulmonary insufficiency, severe arrhythmia, severe arterial stenosis, dissection, etc; (3) Patients with severe cerebrovascular diseases, severe liver diseases, kidney or blood system diseases, or malignant tumors; (4) Individuals with bleeding tendencies or allergic constitution; (5) Patients with pacemakers installed; (6) Pregnant or lactating women, or those with fertility requirements in the past six months; (7) Those who have merged mental illnesses or are unwilling to cooperate; (8) Individuals who have participated or are currently participating in other clinical trials within the past 3 months. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-05-30 00:00:00至 To 2025-01-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-01-31 00:00:00 至 To 2025-01-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由计算机SPSS 26.0产生随机数字,专人负责分配 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The random number sequence was generated by the researcher using the random number table method through SPSS 26.0 software. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
单盲,仅仅对经皮穴位电刺激联合常规治疗组和假经皮穴位电刺激联合常规治疗组(对照组)进行施盲 |
|
Blinding: |
Single blind, blinded only to the transcutaneous electrical acupoint stimulation Combined with Conventional Western Medicine group and the Sham-transcutaneous electrical acupoint stimulation Combined with Conventional Western Medicine group (control group) |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
通过发表论文的形式公开数据,2025年6月份之前。或向研究者说明原因后可联系获取 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Make the data public in the form of published papers, before June 2025.The data of this study are available from the researchers by reasonable request. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
经过培训的研究人员将在病例记录表中收集和记录数据,并使用电子数据采集系统进行数据管理和统计分析,所有保留的数据将被编码以识别患者,而不是个人信息。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Trained researchers will collect and record data in Case Record Form (CRF)and perform data management and statistical analysis using Electronic Data Capture (EDC), and all retained data will be encoded to identify patients rather than personal information. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |